FIELD: biotechnology, immunology and virology.
SUBSTANCE: group of invention relates to biotechnology, immunology and virology. Described is the use of an agent containing component 1 which is in form of expression vector based on recombinant strain human adenovirus serotype 26, in which E1 and E3 regions are deleted, and ORF6-Ad26 is replaced by ORF6-Ad5 with integrated expression cassette selected from SEQ ID NO:1, SEQ ID NO:2, SEQ ID NO:3, and/or component 2 which is in form of expression vector based on recombinant strain human adenovirus serotype 5, in which E1 and E3 regions are deleted with integrated expression cassette selected from в SEQ ID NO:1, SEQ ID NO:2, SEQ ID NO:3. Also used is agent containing component 1, which is an agent in form of expression vector based on recombinant strain human adenovirus serotype 26, in which E1 and E3 regions are deleted, and ORF6-Ad26 is replaced by ORF6-Ad5 with integrated expression cassette selected from SEQ ID NO:1, SEQ ID NO:2, SEQ ID NO:3 and also contains component 2, which is an agent in form of expression vector based on based on recombinant strain simian adenovirus serotype 25, in which E1 and E3 regions are deleted, and ORF6-Ad26 is replaced by ORF6-Ad5 with integrated expression cassette selected from SEQ ID NO:4, SEQ ID NO:2, SEQ ID NO:3 or contains only component 2. Also used is agent containing component 1 which is an agent in form of expression vector based on recombinant strain human simian adenovirus serotype 25, in which E1 and E3 regions are deleted with integrated expression cassette selected from SEQ ID NO:4, SEQ ID NO:2, SEQ ID NO:3 and also contains component 2, which is an agent in form of expression vector based on recombinant strain human adenovirus serotype 5, in which E1 and E3 regions are deleted with integrated expression cassette selected from SEQ ID NO:1, SEQ ID NO:2, SEQ ID NO:3.
EFFECT: group of inventions allows producing safe and effective agents providing prolongation of post-vaccination immunity against SARS-CoV-2 and is aimed at population revaccination against severe acute respiratory syndrome SARS-CoV-2.
7 cl, 8 dwg, 6 tbl, 12 ex
| Title | Year | Author | Number |
|---|---|---|---|
| AGENT FOR INDUCTION OF SPECIFIC IMMUNITY AGAINST SEVERE ACUTE RESPIRATORY SYNDROME CORONAVIRUS (SARS-COV-2) IN LIQUID FORM (VERSIONS) | 2021 |
|
RU2743963C1 |
| AGENT FOR INDUCTION OF SPECIFIC IMMUNITY AGAINST SEVERE ACUTE RESPIRATORY SYNDROME CORONAVIRUS (SARS-COV-2) IN LYOPHILIZED FORM (VERSIONS) | 2021 |
|
RU2743962C1 |
| DRUG APPLICATION FOR INDUCTION OF SPECIFIC IMMUNITY AGAINST SEVERE ACUTE RESPIRATORY SYNDROME VIRUS SARS-COV-2 IN CHILDREN | 2021 |
|
RU2761904C1 |
| USE OF AGENT FOR INDUCTION OF SPECIFIC IMMUNITY AGAINST SEVERE ACUTE RESPIRATORY SYNDROME SARS-COV-2 FOR POPULATION REVACCINATION IN PEOPLE OVER 60 AND/OR WITH CHRONIC DISEASES (VERSIONS) | 2021 |
|
RU2744442C1 |
| PHARMACEUTICAL AGENT AND METHOD FOR USE THEREOF FOR INDUCING SPECIFIC IMMUNITY TO VIRUS OF SEVERE ACUTE RESPIRATORY SYNDROME SARS-COV-2 (EMBODIMENTS) | 2020 |
|
RU2731342C1 |
| EXPRESSION VECTOR FOR CREATING IMMUNOBIOLOGICAL AGENT FOR INDUCING SPECIFIC IMMUNITY TO VIRUS OF SEVERE ACUTE RESPIRATORY SYNDROME SARS-COV-2 (EMBODIMENTS) | 2020 |
|
RU2731356C1 |
| IMMUNOBIOLOGICAL AGENT AND METHOD FOR ITS USE FOR INDUCTION OF SPECIFIC IMMUNITY AGAINST VIRUSES SARS-COV-2 VARIANT B.1.617.2 (DELTA) AND SARS-COV-2 VARIANT B.1.1.529 (OMICRON) (VARIANTS) | 2022 |
|
RU2779634C1 |
| IMMUNOBIOLOGICAL AGENT FOR INDUCING IMMUNE RESPONSE AGAINST LASSA VIRUS AND METHOD FOR USING IT | 2024 |
|
RU2823965C1 |
| Immunobiological agent and method of use thereof for inducing specific immunity against the severe acute respiratory syndrome virus SARS-CoV-2 (embodiments) | 2020 |
|
RU2720614C1 |
| IMMUNOBIOLOGICAL AGENT FOR INDUCING IMMUNE RESPONSE AGAINST SARS-COV-2 AND METHOD FOR USING IT (VERSIONS) | 2021 |
|
RU2765729C1 |
